Incannex Healthcare vs Lisata Therapeutics
IXHL and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IXHL and LSTA compare
Incannex Healthcare is the larger company, worth 2.3 times as much as Lisata Therapeutics ($24.7M against $10.9M).
Incannex Healthcare scores higher on the StockData Score (7 against 6 for Lisata Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IXHL | LSTA |
|---|---|---|
| Size and price | ||
| Market cap | $24.7M | $10.9M |
| Share price | $1.97 | $1.21 |
| Change, 1 year | −82.4% | −44.0% |
| Change, 5 years | – | −92.2% |
| Beta (5Y) | 1.95 | 0.74 |
| Employees | 12 | 21 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 109× |
| P/B | 0.4× (better) | 1.4× |
| FCF yield | −52.1% (better) | −199% |
| Growth | ||
| Revenue growth (TTM) | – | −90.7% |
| Profitability | ||
| Operating margin | – | −22043% |
| Net margin | – | −17159% |
| FCF margin | – | −21662% |
| Return on equity | −47.8% (better) | −137% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 48.81 (better) | 14.09 |
| Altman Z-score | −0.62 (better) | −0.75 |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −280% | −2.1% (better) |
| Shareholder yield | −280% | −2.1% (better) |
| Ownership | ||
| Held by institutions | 3.6% | 12.1% |
| Held by insiders | – | 11.6% |
| Short interest, % of float | – | 0.43% |
Go deeper
- IXHL stock overview
- IXHL income statement
- IXHL valuation and score
- LSTA stock overview
- LSTA income statement
- LSTA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.